Drug Trial Radar · NCT06347016
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
311
Actual
Start
Jul 23, 2024
Primary completion
Jun 17, 2026
Study completion Sep 10, 2026
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Conditions
- Severe Hypertriglyceridemia
Interventions
Plozasiran InjectionDrug
ARO-APOC3 Injection
PlaceboDrug
sterile normal saline (0.9% NaCl)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in fasting serum TG levels from baseline to Month 12 compared to placeboTime frame: Baseline, Month 12
Locations
149 sites in 16 countries. Site status is shown where the registry gives one.
Research Site 1
Birmingham, Alabama
Research Site 2
Mobile, Alabama
Research Site 3
Beverly Hills, California
Research Site 4
Canoga Park, California
Research Site 5
Huntington Beach, California
Research Site 6
Lincoln, California
Research Site 7
Long Beach, California
Research Site 8
Oxnard, California
Research Site 9
Clearwater, Florida
Research Site 10
North Miami, Florida
Research Site 11
Sarasota, Florida
Research Site 12
Lawrenceville, Georgia
Research Site 13
Sugar Hill, Georgia
Research Site 14
Elkhart, Indiana
Research Site 15
Indianapolis, Indiana
Research Site 16
South Bend, Indiana
Research Site 17
Overland Park, Kansas
Research Site 18
Topeka, Kansas
Research Site 19
Metairie, Louisiana
Research Site 20
Annapolis, Maryland
Research Site 21
Jackson, Mississippi
Research Site 22
Fremont, Nebraska
Research Site 23
Norfolk, Nebraska
Research Site 24
Morristown, New Jersey
Research Site 26
New York, New York
Research Site 27
Riverhead, New York
Research Site 25
The Bronx, New York
Research Site 28
Asheboro, North Carolina
Research Site 29
Wilmington, North Carolina
Research Site 30
Beavercreek, Ohio
Research Site 31
Columbus, Ohio
Research Site 32
Oklahoma City, Oklahoma
Research Site 33
Horsham, Pennsylvania
Research Site 34
Newport, Pennsylvania
Research Site 35
Philadelphia, Pennsylvania
Research Site 36
Philadelphia, Pennsylvania
Research Site 37
Fort Mill, South Carolina
Research Site 38
Greenville, South Carolina
Research Site 39
Chattanooga, Tennessee
Research Site 40
Fort Worth, Texas
Showing 40 of 149 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.